NCT05809830View on ClinicalTrials.gov

Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

May 29, 2023

Primary Completion Date

June 20, 2025

Study Completion Date

May 8, 2026

Conditions
Advanced Soft-tissue Sarcoma
Interventions
DRUG

LB-100 plus Doxorrubicin

In Phase one the intervention will be LB-100 plus Doxorrubicin. The experimental arm in Phase II will also be LB-100 plus Doxorrubicin

DRUG

Doxorubicin

The control arm in Phase II will be Doxorrubicin alone

Trial Locations (6)

28040

Hospital Clínico San Carlos, Madrid

Hospital Fundación Jiménez Díaz, Madrid

28046

Hospital Universitario La Paz, Madrid

30120

Hospital Clínico Universitario Virgen de la Arrixaca, Murcia

46010

Hospital Clínico Universitario de Valencia, Valencia

08026

Hospital de la Santa Creu i Sant Pau, Barcelona

All Listed Sponsors
lead

Grupo Espanol de Investigacion en Sarcomas

OTHER